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The objectives of our study were to: characterise the expression of P21
waf-1 and p53 proteins in advanced stage prostate cancer; determine the relationship between p53 and p21 protein expressions; correlate p53 and p21 expression to clinical outcome; and assess the value of arti®cial neural network (ANN) in predicting prostate cancer survival.
Method
Tissue specimens were obtained from 75 patients with advanced prostate cancer (clinical stage C, 11 patients; stage D1, eight patients; stage D2, 56 patients) who underwent androgen ablation and studied immunohistochemically for p53 (Mab D07) and p21
waf-1 (Mab EA10). The samples were obtained before the patients received hormonal therapy. Clinical outcome was analysed using the Kaplan±Meier method and log-rank tests. The Cox proportional hazard model was used to determine the independence of multiple variables in relation to survival. Finally, neural network modelling was attempted to identify a combination of factors predictive of outcome. ANN with a backpropagation algorithm was used, based on the ®ve conventional clinical parameters (age, prostate-speci®c antigen (PSA), stage, grade, number of bone lesions) and three experimental markers (p21, p53, and neuroendocrine (NE) differentiation).
Results
Of the cases, 33.3% expressed p53 immunoreactivity and 33.3% expressed p21 immunoreactivity. There was no statistically signi®cant correlation between p21 and p53 expression either in the entire study group (n 75) or in stage D2 cases (n 56; P 0.38 and P 0.68, respectively). Overall survival was signi®cantly related to p21 expression (P 0.0006 for the entire group and P 0.01 for the D2 cases). There was no statistically signi®cant difference in survival between p53 positive or negative cases (P 0.38 overall; P 0.7 stage D2 only). Multivariate analysis was performed on the survival data using the following variables: age at diagnosis, pre-treatment serum PSA, clinical stage, number of bone lesions, biopsy type, and p53 and p21 expression. The number of bone lesions and p21 protein expression were the only statistically independent variables associated with shorter survival. Finally, Table 1 shows the results with ANN in predicting poor survival. 
Conclusion
Our data suggest that p53 protein expression has no relation to prognosis in advanced stage prostate cancer. However, p21 protein expression appears to be a strong and independent poor prognostic factor in patients with advanced stage prostate cancer treated with androgen ablation. In addition, this preliminary study demonstrated the potential value of ANN in the analysis of prognostic markers in prostate cancer. The results obtained by this method indicate that such an approach may provide a potentially useful tool for evaluating novel prognostic markers.
